Skip to main content

Table 4 Falsification endpoint analysis

From: Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis

  

Rate per 100 (95% CI)

   
 

Before propensity score matching

After propensity score matching

Hazard ratio (95% CI)

p value

 

No metformin (n = 2222)

Metformin (n = 1100)

No metformin (n = 2222)

Metformin (n = 1100)

Fracture

4.57 (3.81, 5.48)

2.54 (1.75, 3.68)

4.00 (3.05, 5.25)

3.01 (2.05, 4.4)

0.75 (0.45, 1.21)

0.23